Last reviewed · How we verify

Cardizem — Competitive Intelligence Brief

Cardizem (diltiazem) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (non-dihydropyridine, benzothiazepine). Area: Cardiovascular.

marketed Calcium channel blocker (non-dihydropyridine, benzothiazepine) Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cardizem (diltiazem) — Generic (originally Tanabe Seiyaku).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cardizem TARGET diltiazem Generic (originally Tanabe Seiyaku) marketed Calcium channel blocker (non-dihydropyridine, benzothiazepine) Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1 1982-11-05

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (non-dihydropyridine, benzothiazepine) class)

  1. Generic (originally Tanabe Seiyaku) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cardizem — Competitive Intelligence Brief. https://druglandscape.com/ci/diltiazem. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: